We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > News
Cannabis & Psychedelics News

Missouri Launches Its Legal Recreational Cannabis Market Early

Adult-use, recreational cannabis became legally available in Missouri on Friday, February 3 – three days earlier than planned.

Read More

Vermont Regulator Stops the Sale of Contaminated Cannabis Flower

The CCB “has verified” that multiple samples of Holland Cannabis flower tested above the action limits for myclobutanil, a chemical used as a fungicide.

Read More

Australia to Permit MDMA and Psilocybin Prescriptions

From July 1, psychiatrists in Australia will be allowed to prescribe MDMA and psilocybin as treatments for certain mental health conditions.

Read More

UK’s Health Service Can Now Prescribe Epidiolex For Tuberous Sclerosis Complex

The change comes after the National Institute for Health and Care Excellence (NICE) issued final guidance recommending its use.

Read More

Yale University to Establish a Center For Cannabis Research

The Yale Center for the Science of Cannabis and Cannabinoids will foster studies into the acute and chronic effects of cannabinoids on neuronal and mental health.

Read More

No Link Between Legal Cannabis and Psychosis Diagnoses, Study Finds

Legalizing cannabis does not affect psychosis diagnoses or the prescription of antipsychotic medicines, a new study published in JAMA Network Open has found.

Read More

Colorado Regulator Issues Warning About Moldy Flower

State regulators in Colorado have issued another health and safety notice after “potentially unsafe levels” of total yeast and mold and Aspergillus were found in a batch of cannabis flower.

Read More

Oregon Regulator Recalls 1,000 Cannabis Vapes

The products had tested positive for two pesticides, piperonyl butoxide and a pyrethrin.

Read More

FDA Defers to Congress For CBD Food and Supplement Regulations

The federal agency made its decision following a “careful review” of the potential regulatory pathways of CBD products in the US.

Read More

 
Advertisement